Strategic positioning in the cell and gene therapy market has expanded, with the company now exclusively servicing nearly half the market via its 3PL and Specialty distribution infrastructure. The 'Other' growth businesses (at-Home, Nuclear, and OptiFreight) collectively delivered double-digit profit growth, validating the strategy to prioritize these specialized, higher-margin assets. Performance in fiscal 2026 was driven by resilient demand in Pharmaceutical and Specialty Solutions, particularly upstream and downstream Specialty strength which grew over 25%. Pharma segment revenue growth of 3% to 5% incorporates a headwind from IRA price changes, which are expected to have a consistent percentage impact to revenue as seen in H2 2026 but no adverse profit impact. Specialty revenue is projected to grow at double-digit rates, supported by new customer wins in Biopharma Solutions and the expansion of multi-specialty MSO platforms.